Zimmer Biomet Holdings, Inc.

- There is no mention of any current or planned fundraising through new debt or equity in the provided transcript. - The company continues to assume up to $750 million of share repurchases remain unchanged, indicating share buybacks rather than issuance. - Interest expense, tax rate, and share count guidance remain stable, suggesting no new significant debt issuance planned. - Focus appears to be on operational excellence, innovation, and go-to-market transformation funded internally. - No discussion of new financing rounds, equity offerings, or debt raises was made during the Q&A or remarks.

- Zimmer Biomet is investing heavily in innovation and go-to-market transformation, including technology launches like Monogram (expected early 2027) and expansion of the sales force with over 200 new reps specifically for Monogram. - The company is expanding its manufacturing footprint into lower-cost geographies to improve operational efficiency and margins. - There is a sizable investment focus on building clinical evidence, economic strategy, and new customer targeting strategies to drive adoption of new products. - Zimmer Biomet committed as the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund focusing on breakthrough technologies such as AI, data applications, and cartilage repair. - Hiring Dr. Jonathan [indiscernible] as Chief Science Technology and Medical Affairs Officer to lead strategy and innovation around AI-enabled robotics, software, smart implants, and connected technologies. - Investments support future-proofing the company and building a robust technology portfolio, including connected and robotic solutions (Monogram, ROSA, TMINI).

- U.S. business grew 3.2% in Q1 2026; international grew 2.5%. - Overall organic constant currency revenue growth guidance for 2026 maintained at 1% to 3%. - Growth expected to be roughly consistent throughout 2026. - Paragon 28 acquisition to contribute ~100 basis points to reported sales growth in 2026. - Technology and data, bone cement, surgical business grew nearly 12% in Q1 driving growth. - Knee market: U.S. knees grew 2.2% with strong partial knee sales; hips grew 5% in the U.S. - International markets expected mid-single digit growth in second half of 2026. - Monogram robotic system launch anticipated in early 2027 expected to drive future growth. - Sales force transformation enhancing productivity and specialty focus to support growth. - Pricing erosion expected up to 100 basis points in 2026, consistent with guidance. - Free cash flow growth guidance raised to 9%-11% for 2026.

- Zimmer Biomet raised its 2026 adjusted EPS guidance to $8.40 to $8.55, up from $8.30 to $8.45. - Free cash flow growth guidance increased to 9% to 11%, from the previous 8% to 10%. - Operating margins for 2026 are expected to be slightly down, better than previously anticipated, with a modest decline of less than 50 basis points from 2025, despite investments and acquisition dilution. - Q2 2026 operating margins are expected to be down roughly 200 basis points from Q2 2025; Q3 expected to improve sequentially by about 50 basis points. - Pricing pressures anticipated with a full-year assumption of up to 100 basis points of price erosion. - The company remains confident in the direction given strong Q1 results, ongoing go-to-market transformations, and robust innovation pipeline, with updates expected in the August call.

The provided transcript does not explicitly mention current or expected order book or pending orders figures. However, relevant insights related to demand and sales momentum include: - International markets expect mid-single digit growth in the second half of 2026 after some disruptions and distributor changes (Page 9). - The U.S. market shows solid growth with a 4-4.5% durable market growth rate, though knees need acceleration and hips expected to improve (Page 12). - Technology sales, including robotics and new products like Monogram and ROSA, grew 30% in Q1 supporting future order potential (Pages 8-9). - Sales force transformation progressing, with improved productivity and increasing dedicated reps, supporting stronger sales execution ahead (Pages 6-7). - No specific quantification of the order backlog or pending orders was disclosed during the call.